U.S. Markets closed

Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress

Stock Monitor: ImmuCell Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Stemline Therapeutics, Inc. (NASDAQ: STML), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=STML as the Company's latest news hit the wire. On May 18, 2018, the Company announced that its SL-401 will be the subject of three clinical presentations, including an oral presentation on the pivotal blastic plasmacytoid dendritic cell neoplasm (BPDCN) program, at the upcoming 23rd Congress of the European Hematology Association (EHA), to be held from June 14-17, 2018, in Stockholm, Sweden. Updated data from the ongoing Phase-2 trial in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) will also be presented. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for ImmuCell Corporation (NASDAQ: ICCC), which also belongs to the Healthcare sector as the Company Stemline Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Stemline Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Details of the EHA Congress Presentations

  • Results of Pivotal Phase-2 Trial of SL-401 in Patients with BPDCN;
  • Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory MF;
  • Results from Ongoing Phase-1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML

Stemline Continues to Report Encouraging Signs of Clinical Activity and Safety in Indications Beyond BPDCN, Including CMML and MF

Ivan Bergstein, M.D., Chief Executive Officer at Stemline, stated that the Company is honored to be showcasing, via an oral presentation, the results of its SL-401 pivotal trial in BPDCN to a European audience via the EHA Congress. The Company believes that this selection underscores SL-401's robust clinical data and increased global awareness of BPDCN, a devastating malignancy of high unmet medical need. Ivan added that in the U.S., Stemline remains on track to complete its rolling Biologics License Application (BLA) submission this quarter. In Europe, the Company anticipates feedback later in 2018 from the European Medicines Agency (EMA) regarding the timing of a potential regulatory filing in the European Union.

Ivan further added that Stemline and its investigators continue to report encouraging signs of clinical activity and safety in indications beyond BPDCN, including CMML and MF, and the Company looks forward to presenting updated data from these indications at the conference.

Stemline to Present SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting

On May 17, 2018, the Company also announced that clinical data from SL-801 and SL-701 trials were selected for poster presentations at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 1-5, 2018, at McCormick Place in Chicago, Illinois. The topics of the presentation include Phase-2 Trial of SL-701 in Relapsed/Refractory Glioblastoma (GBM): Correlation of Immune Response with Longer-Term Survival; and Interim Results from A Phase-1 Trial of SL-801, A Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors.

About Stemline Therapeutics, Inc.

Headquartered in New York City, New York, Stemline Therapeutics is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical-stage product candidates, SL-401, SL-701, and SL-801.

About SL-401

SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a range of malignancies. SL-401 has completed a pivotal trial in BPDCN, for which it was granted breakthrough therapy designation (BTD). SL-401 is also being evaluated in clinical trials in additional indications including CMML, MF, acute myeloid leukemia (AML), and myeloma.

Stock Performance Snapshot

May 21, 2018 - At Monday's closing bell, Stemline Therapeutics' stock ended the trading session flat at $19.45.

Volume traded for the day: 166.38 thousand shares.

Stock performance in the last month – up 12.43%; previous three-month period – up 23.10%; past twelve-month period – up 132.93%; and year-to-date - up 24.68%

After yesterday's close, Stemline Therapeutics' market cap was at $589.14 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors